Financials

News Ideas Technicals Forecast

REGN fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Regeneron Pharmaceuticals, Inc. key financial stats and ratios

REGN price-to-sales ratio is 7.76. The company has an Enterprise Value to EBITDA ratio of 19.31. As of 2023 they employed 13.45 k people.

Statistics

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

‪0.00‬

Price to earnings ratio

Price to cash flow ratio

Currency: USD

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Current

Key stats

—

—

—

—

—

—

—

—

Valuation ratios

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Profitability ratios

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Liquidity ratios

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

Solvency ratios

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—